Clinical Trials

Open Clinical Trials

Solid Tumor AML HPV 16-Positive Cancers

RTX-240 for the Treatment of Advanced Solid Tumors

Study Title
Open label, multicenter, multidose, first-in-human Phase 1/2 study of RTX-240 for the treatment of patients with relapsed/refractory or locally advanced solid tumors
Status

Enrolling

Key Objectives
  1. Safety Assessment
  2. Pharmacodynamics of RTX-240 will be evaluated through changes in natural killer and T cell numbers relative to baseline
  3. Anti-tumor activity of RTX-240 measured by Overall Response Rate, or ORR

If you are a patient or a loved one interested in learning more about RTX-240 for the treatment of cancer or participating in a clinical trial, please visit:

RubiusTrials.com ClinicalTrials.gov

RTX-240 for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Study Title
Open label, multicenter, multidose, first-in-human Phase 1 study of RTX-240 for the treatment of patients with relapsed or refractory acute myeloid leukemia
Status

Enrolling

Key Objectives
  1. Safety Assessment
  2. Pharmacodynamics of RTX-240 will be evaluated through changes in natural killer and T cell numbers relative to baseline
  3. Anti-tumor activity of RTX-240 measured by Overall Response Rate, or ORR

If you are a patient or a loved one interested in learning more about RTX-240 for the treatment of cancer or participating in a clinical trial, please visit:

RubiusTrials.com ClinicalTrials.gov

RTX-321 for the Treatment of HPV 16-Positive Cancers

Study Title
Open-label, multicenter, multiple-ascending dose, first-in-human, Phase 1 study of RTX-321 for the treatment of patients that are HLA-A*02:01 positive with persistent, recurrent, or metastatic, unresectable, HPV 16-positive cancers (including cervical cancer, head and neck cancer – including of the nasal and oral cavities, larynx, hypopharynx, nasopharynx, and oropharynx – and anal cancer)
Status

Recruiting

Key Objectives
  1. Safety Assessment
  2. Pharmacodynamics of RTX-321 will be evaluated through changes in number of CD8+ T-cells in peripheral blood
  3. Anti-tumor activity of RTX-321 measured by Duration of Response (DoR), Progression Free Survival (PFS), Overall Response Rate (ORR) and Overall Survival (OS)

If you are a patient or a loved one interested in learning more about RTX-321 for the treatment of cancer or participating in a clinical trial, please visit:

ClinicalTrials.gov